The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis
Open accessAbstract
BACKGROUND: The Janus kinase (JAK) family of tyrosine kinases includes JAK1, JAK2, JAK3 and TYK2, and is required for signaling through Type I and Type II cytokine receptors. CP-690,550 is a potent and selective JAK inhibitor currently in clinical trials for rheumatoid arthritis (RA) and other autoimmune disease indications. In RA trials, dose-dependent decreases in neutrophil counts (PBNC) were observed with CP-690,550 treatment. These studies were undertaken to better understand the relationship between JAK selectivity and PBNC decreases observed with CP-690,550 treatment. METHODS: Potency and selectivity of CP-690,550 for mouse, rat and human JAKs was evaluated in a panel of in vitro assays. The effect of CP-690,550 on granulopoiesis from progenitor cells was also assessed in vitro using colony forming assays. In vivo the potency of orally administered CP-690,550 on arthritis (paw edema), plasma cytokines, PBNC and bone marrow differentials were evaluated in the rat adjuvant-induced arthritis (AIA) model. RESULTS: CP-690,550 potently inhibited signaling through JAK1 and JAK3 with 5-100 fold selectivity over JAK2 in cellular assays, despite inhibiting all four JAK isoforms with nM potency in in vitro enzyme assays. Dose-dependent inhibition of paw edema was observed in vivo with CP-690,550 treatment. Plasma cytokines (IL-6 and IL-17), PBNC, and bone marrow myeloid progenitor cells were elevated in the context of AIA disease. At efficacious exposures, CP-690,550 returned all of these parameters to pre-disease levels. The plasma concentration of CP-690,550 at efficacious doses was above the in vitro whole blood IC50 of JAK1 and JAK3 inhibition, but not that of JAK2. CONCLUSION: Results from this investigation suggest that CP-690,550 is a potent inhibitor of JAK1 and JAK3 with potentially reduced cellular potency for JAK2. In rat AIA, as in the case of human RA, PBNC were decreased at efficacious exposures of CP-690,550. Inflammatory end points were similarly reduced, as judged by attenuation of paw edema and cytokines IL-6 and IL-17. Plasma concentration at these exposures was consistent with inhibition of JAK1 and JAK3 but not JAK2. Decreases in PBNC following CP-690,550 treatment may thus be related to attenuation of inflammation and are likely not due to suppression of granulopoiesis through JAK2 inhibition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Enzyme kinetics; behavior and analysis of rapid equilibrium and steady state enzyme systems
(1994) · International Journal of Biochemistry · doi:10.1016/0020-711x(94)90021-3 · Cited by 2,972
A quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466
Interleukin-6 and chronic inflammation.
Gabay, C. (2006) · Arthritis Research & Therapy · doi:10.1186/ar1917 · Cited by 1,693
Jak2 Is Essential for Signaling through a Variety of Cytokine Receptors
Parganas, E., Wang, D., Stravopodis, D., Topham, D. J., Marine, J.-C., Teglund, S., Vanin, E. F., Bodner, S., Colamonici, O. R., van Deursen, J. M., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81167-8 · Cited by 1,156
Jak2 Deficiency Defines an EssentialDevelopmental Checkpoint in DefinitiveHematopoiesis
Neubauer, H., Cumano, A., Müller, M., Wu, H., Huffstadt, U., & Pfeffer, K. (1998) · Cell · doi:10.1016/s0092-8674(00)81168-x · Cited by 914
Rodig, S. J., Meraz, M. A., White, J. M., Lampe, P. A., Riley, J. K., Arthur, C. D., King, K. L., Sheehan, K. C. F., Yin, L., Pennica, D., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81166-6 · Cited by 853
Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor
Changelian, P. S., Flanagan, M. E., Ball, D. J., Kent, C. R., Magnuson, K. S., Martin, W. H., Rizzuti, B. J., Sawyer, P. S., Perry, B. D., Brissette, W. H., et al. (2003) · Science · doi:10.1126/science.1087061 · Cited by 607
Wipke, B. T., & Allen, P. M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.3.1601 · Cited by 585
A new modality for immunosuppression: targeting the JAK/STAT pathway
O'Shea, J. J., Pesu, M., Borie, D. C., & Changelian, P. S. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1441 · Cited by 303
Selectivity and therapeutic inhibition of kinases: to be or not to be?
Ghoreschi, K., Laurence, A., & O'Shea, J. J. (2009) · Nature Immunology · doi:10.1038/ni.1701 · Cited by 241
IL-17 and Th17 cells in human inflammatory diseases
Miossec, P. (2009) · Microbes and Infection · doi:10.1016/j.micinf.2009.04.003 · Cited by 236
Identification of SH2-Bβ as a potent cytoplasmic activator of the tyrosine kinase Janus kinase 2
Rui, L., & Carter‐Su, C. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.13.7172 · Cited by 158
The Novel JAK-3 Inhibitor CP-690550 Is a Potent Immunosuppressive Agent in Various Murine Models
Kudlacz, E. M., Perry, B. D., Sawyer, P. S., Conklyn, M. J., McCurdy, S. P., Brissette, W. H., and, M. F., & Changelian, P. S. (2003) · American Journal of Transplantation · doi:10.1046/j.1600-6143.2003.00281.x · Cited by 154
Boy, M. G., Wang, C., Wilkinson, B. E., Chow, V. F.-S., Clucas, A., Krueger, J. G., Gaweco, A. S., Zwillich, S. H., Changelian, P. S., & Chan, G. L. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.25 · Cited by 142
Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis
Milici, A. J., Kudlacz, E. M., Audoly, L., Zwillich, S. H., & Changelian, P. S. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2365 · Cited by 142
Brizzi, M. F., Aronica, M. G., Rosso, A., Bagnara, G. P., Yarden, Y., & Pegoraro, L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.7.3562 · Cited by 137
Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs
Pesu, M., Candotti, F., Husa, M., Hofmann, S. R., Notarangelo, L. D., & O’Shea, J. J. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00220.x · Cited by 134
Macrophage- and neutrophil- dominant arthritis in human IL-1α transgenic mice
Niki, Y., Yamada, H., Seki, S., Kikuchi, T., Takaishi, H., Toyama, Y., Fujikawa, K., & Tada, N. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11530 · Cited by 100
Neutrophil apoptosis in rheumatoid arthritis is regulated by local oxygen tensions within joints
Cross, A. L., Barnes, T. C., Bucknall, R. C., Edwards, S. W., & Moots, R. J. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.0306178 · Cited by 96
Parsonage, G. N., Filer, A. D., Bik, M., Hardie, D. L., Lax, S., Howlett, K. A., Church, L. D., Raza, K., Wong, S. H., Trebilcock, E., et al. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2406 · Cited by 93
Ottonello, L. C., Cutolo, M., Frumento, G., Arduino, N., Bertolotto, M., Mancini, M., Sottofattori, E., & Dallegri, F. (2002) · British journal of rheumatology · doi:10.1093/rheumatology/41.11.1249 · Cited by 92
Cedergren, J., Forslund, T., Sundqvist, T., & Skogh, T. (2007) · PubMed · Cited by 85
Katano, M., Okamoto, K., Arito, M., Kawakami, Y., Kurokawa, M. S., Suematsu, N., Shimada, S., Nakamura, H., Xiang, Y., Masuko, K., et al. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2587 · Cited by 78
van Gurp, E., Weimar, W. W., Gaston, R. S., Brennan, D. C., Mendez, R., Pirsch, J. D., Swan, S. K., Pescovitz, M. D., Ni, G., Wang, C., et al. (2008) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2008.02307.x · Cited by 76
Auer, J., Blaess, M. F., Schulze‐Koops, H., Rußwurm, S., Nagel, T., Kalden, J. R., Röllinghoff, M., & Beuscher, H. U. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2294 · Cited by 75
Lin, T. H., Hegen, M., Quadros, E., Nickerson‐Nutter, C. L., Appell, K. C., Cole, A. G., Shao, Y., Tam, S., Ohlmeyer, M. H. J., Wang, B., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27536 · Cited by 74
JAK3 inhibition, a viable new modality of immunosuppression for solid organ transplants
Borie, D. C., O’Shea, J. J., & Changelian, P. S. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.09.007 · Cited by 72
Conklyn, M. J., Andresen, C. J., Changelian, P. S., & Kudlacz, E. M. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0504282 · Cited by 71
Manshouri, T., Quintás‐Cardama, A., Nussenzveig, R. H., Gaikwad, A. S., Estrov, Z. E., Prchal, J. T., Cortes, J. E., Kantarjian, H. M., & Verstovšek, S. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00817.x · Cited by 62
Issekutz, A. C., Ayer, L. M., Miyasaka, M., & Issekutz, T. B. (1996) · Immunology · doi:10.1046/j.1365-2567.1996.d01-695.x · Cited by 62
Ortmann, R., Cheng, T. P., Visconti, R., Frucht, D. M., & O’Shea, J. J. (2000) · Arthritis Research · doi:10.1186/ar66 · Cited by 62
Leeuwen, M. A. V., Westra, J., Limburg, P. C., van Riel, P. L., & van Rijswijk, M. H. (1995) · Annals of the Rheumatic Diseases · doi:10.1136/ard.54.1.33 · Cited by 54
Anti-neutrophil monoclonal antibody therapy inhibits the development of adjuvant arthritis
Santos, L. L., Morand, E. F., Hutchinson, P. E., Boyce, N., & Holdsworth, S. R. (1997) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.1997.263-ce1154.x · Cited by 53
Hematopoietic Colony-Forming Cell Assays
Pereira, C. C., Clarke, E., & Damen, J. (2007) · Methods in molecular biology · doi:10.1007/978-1-59745-536-7_14 · Cited by 45
Inflammatory cells and bone loss in rheumatoid arthritis
Haynes, D. R. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2213 · Cited by 28
Gupta, P. K., Friberg, L. E., Karlsson, M. O., Krishnaswami, S., & French, J. L. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009346060 · Cited by 21
Stopping the traffic: A route to arthritis therapy
Hallett, M. B., & Williams, A. S. (2008) · European Journal of Immunology · doi:10.1002/eji.200838786 · Cited by 8
Cited by
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Johnson, D. E., O'Keefe, R. A., & Grandis, J. R. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.8 · Cited by 3,110
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis
Ytterberg, S. R., Bhatt, D. L., Mikuls, T. R., Koch, G. G., Fleischmann, R., Rivas, J. L., Germino, R., Menon, S., Sun, Y., Wang, C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2109927 · Cited by 1,816
Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
Fleischmann, R., Kremer, J., Cush, J., Schulze-Koops, H., Connell, C. A., Bradley, J. D., Gruben, D., Wallenstein, G. V., Zwillich, S. H., & Kanik, K. S. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109071 · Cited by 1,024
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
van Vollenhoven, R. F., Fleischmann, R., Cohen, S., Lee, E. B., García Meijide, J. A., Wagner, S., Forejtova, S., Zwillich, S. H., Gruben, D., Koncz, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112072 · Cited by 945
Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
Sandborn, W. J., Ghosh, S., Panes, J., Vranic, I., Su, C., Rousell, S., & Niezychowski, W. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112168 · Cited by 800
Metadata
- Authors
- Meyer, D. M., Jesson, M. I., Li, X., Elrick, M. M., Funckes-Shippy, C. L., Warner, J. D., Gross, C. J., Dowty, M. E., Ramaiah, S. K., Hirsch, J. L., Saabye, M. J., Barks, J. L., Kishore, N., & Morris, D. L.
- Venue
- Journal of Inflammation
- Published
- 2010
- Volume
- 7
- Issue
- 1
- Pages
- 41
- ISSN
- 1476-9255 (ISSN-L)
- OpenAlex
- W2149189075
- Cited by
- 461
- References
- 37
- FWCI
- 14.45
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.